Dr. Aljitawi: The first step is we have to make the Matrix in a very standardized way, so that Matrix A, B or C all have the same components, which potentially is very achievable.
The second process is to generate data showing the effectiveness of this Matrix and capturing why the cells become resistant to chemotherapy.
Third, if we can show in the lab that, in a predictable way, adding different drugs to these leukemia cells in this matrix can reproduce the same results.
Once we have that, I think we can really translate that to human use, to clinical use.
To make it standardized needs some industrialization of a biologic agent. With our bioengineering capabilities, we’ll be able to get there.
